Loading
The first drug that blocks all active RAS variants, approved by the FDA in August 2026 for metastatic pancreatic cancer, where KRAS drives 90% of tumours.
Daraxonrasib is Revolution Medicines' tri-complex inhibitor. Phase 1/2: median OS ~14.5 months in second-line pancreatic cancer versus historical ~6 months. RASolute 302 (second-line PDAC) supported FDA approval on 26 August 2026 as Rasonque for metastatic pancreatic cancer; RASolute 303 (first-line) and the NSCLC phase 3 (RASolve 301) continue. Rash and stomatitis are the main toxicities.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Binds cyclophilin A to form a tri-complex that sterically blocks RAS(ON) from engaging effectors, across G12X/G13X/Q61X and wild-type RAS. Connects to KRAS.
1.Drug binds cyclophilin A inside the cell
Source: clinicaltrials.gov/study/NCT06625320. Doses are for orientation; the current label governs.
Sources: NICE search: daraxonrasib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
Breakthrough Therapy designation, previously treated metastatic PDAC source
NDA 220910 received by the FDA on the RASolute 302 result source
NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy source
| Region | Year | Indication |
|---|---|---|
| US | 2026 | Metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or in adults who are not candidates for multiagent systemic therapy · Rasonque, NDA 220910, 26 August 2026 |
| Adverse event |
|---|
| Rash |
| Stomatitis |
| Nausea |
| Diarrhoea |
| Fatigue |
Most common; mostly grade 1-2 per phase 1/2 reports. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | FDA-approved 26 August 2026 (Rasonque, NDA 220910), oral tablets; coverage decisions and list price not yet recorded | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
One of the most cited trial reports Europe PMC returns for Daraxonrasib in Pancreatic ductal adenocarcinoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
The mechanism that let one drug address G12D, G12V and G12R together, which is why the RASolute 302 trial could enrol unselected pancreatic cancer and nearly double survival.
The most frequently mutated oncogene in cancer stopped being undruggable, and patients with KRAS G12C lung and bowel cancers now have targeted pills. The approach, exploiting a mutation-created chemical handle and an inactive-state pocket, has become a template for other hard targets.
Query for this drug: (TITLE:"Daraxonrasib" OR ABSTRACT:"Daraxonrasib" OR TITLE:"Rasonque" OR ABSTRACT:"Rasonque" OR TITLE:"RMC-6236" OR ABSTRACT:"RMC-6236") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Daraxonrasib, not a curated reading list.
Shares Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC, Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors, Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors, Revolution Medicines.
Shares Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS, Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut, CodeBreaK 100 (pancreatic cancer cohort), Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
Shares CodeBreaK 100 (pancreatic cancer cohort), Covalent chemistry for the RAS mutations that still have no drug, Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable, KRAS roadmap: undruggable → G12C → pan-RAS.
Shares Covalent chemistry for the RAS mutations that still have no drug, Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable, KRAS roadmap: undruggable → G12C → pan-RAS, Pancreatic cancer (KEGG map).
Shares Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors.
Shares RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, KRAS & RAS inhibitors, The undruggable drivers.
Shares Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors.
Shares CodeBreaK 100 (pancreatic cancer cohort), Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable, KRAS roadmap: undruggable → G12C → pan-RAS, KRAS G12C-mutant pancreatic ductal adenocarcinoma.